Adherence to long-term use of reninangiotensin II-aldosterone system inhibitors in children with chronic kidney disease

Although renin-angiotensin II-aldosterone system inhibitor (RASI) use for renal protection is welldocumented, adherence to RASI therapy in the pediatric population is unclear. This study aimed to evaluate patient characteristics associated with adherence to chronic RASI use in patients with childhood chronic kidney disease (CKD).